Cost of Revenue Trends: Catalent, Inc. vs Perrigo Company plc

Catalent vs Perrigo: Cost of Revenue Trends Unveiled

__timestampCatalent, Inc.Perrigo Company plc
Wednesday, January 1, 201412291000002613100000
Thursday, January 1, 201512155000002891500000
Friday, January 1, 201612605000003228800000
Sunday, January 1, 201714208000002966700000
Monday, January 1, 201817108000002900200000
Tuesday, January 1, 201917129000003064100000
Wednesday, January 1, 202021110000003248100000
Friday, January 1, 202126460000002722500000
Saturday, January 1, 202231880000002996200000
Sunday, January 1, 202332160000002975200000
Monday, January 1, 20243428000000
Loading chart...

Unleashing the power of data

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding cost trends is crucial. Catalent, Inc. and Perrigo Company plc, two giants in the sector, have shown distinct trajectories in their cost of revenue from 2014 to 2023. Catalent's cost of revenue has surged by approximately 179% over this period, reflecting its aggressive expansion and increased production capabilities. In contrast, Perrigo's costs have remained relatively stable, with a modest increase of around 14%, indicating a more conservative growth strategy.

Key Insights

  • Catalent's Growth: From 2014 to 2023, Catalent's cost of revenue grew from $1.23 billion to $3.22 billion, showcasing its dynamic growth strategy.
  • Perrigo's Stability: Perrigo's costs fluctuated slightly, peaking in 2020, but overall remained steady, highlighting its focus on efficiency.

These trends offer a window into the strategic priorities of each company, with Catalent focusing on expansion and Perrigo on maintaining operational efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025